Healius (ASX:HLS) has completed its operating & strategic review culminating in the sale of its Lumus Imaging unit for AU$965 million, according to a Thursday Australian bourse filing.
The sale to Affinity Equity Partners is expected to complete on May 1 and its proceeds will be used to pay shareholders a special dividend of AU$0.41 per share.
After the Lumus sale, the company said it would save AU$15 million to AU$20 million in costs by cutting unallocated corporate costs and pathology expenses.
The company's shares were up 13% in recent Thursday trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。